Skip to search formSkip to main contentSkip to account menu

MS 325

Known as: MS-325 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
We report the synthesis of macrocyclic DTPA conjugates of 2,2'-diaminobiphenyl and their Gd complexes of the type [Gd(L)(H(2)O… 
2007
2007
Ziele: Erprobung des intravaskularen Kontrastmittels MS-325 (Vasovist, Schering, Berlin) zur Darstellung infarzierten Myokards… 
2006
2006
2006
PURPOSE To compare the signal-to-noise and contrast-to-noise ratio as well as the image quality of 3D inversion recovery steady… 
2005
2005
The synthesis of a novel ligand, based on N-methyl-diethylenetriaminetetraacetate and containing a diphenylcyclohexyl serum… 
2001
2001
Preliminary results on MS-325 versus ProHance enhanced magnetic resonance angiography (MRA) at low field strength in a rabbit… 
2000
2000
EPIX is developing MS-325 (AngioMARK), an intravascular magnetic resonance contrast agent for use in the imaging of blood vessels… 
2000
2000
EPIX is developing MS-325 (AngioMARK), an intravascular magnetic resonance contrast agent for use in the imaging of blood vessels… 
2000
2000
Serial high resolution MR imaging (3D SPGR, 11=1.7=35) of the perineum was performed in sixteen healthy, sexually functional… 
Review
1997
Review
1997
SummeryThe value of macromolecular contrast agents (MMCM) for the characterization of benign and malignant breast tumors will be…